American pharmaceutical giant Pfizer on 26 May informed the Central government that its COVID-19 vaccine is suitable for all aged 12 and above and can be stored at 2-8 degrees for over a month.

For our comprehensive coverage and latest updates on COVID-19 click here.

They (Pfizer and the Indian government) also discussed the indemnity protection against liabilities and asked for relaxations in some clauses before the company brings its COVID-19 vaccines to India, the sources added. The drugmaker is likely to supply 50 million COVID-19 vaccines to India in 2021, albeit with a few conditions, sources told ANI on 25th May.

Meanwhile, Moderna, another pharmaceutical giant in the US, sources said, is expecting to start manufacturing its COVID-19 vaccines in India following analysis with Cipla, a pharmaceutical company based in Mumbai, among other Indian firms. Earlier, both drugmakers had allegedly refused to send vaccines directly to the state governments of Delhi and Punjab, claiming that they will only deal with the Central government.